Skip to content
SpinStreet24

Trump Reveals Agreements to Reduce US Weight-Loss Drug Prices

GLP-1 drugs
Zepbound and Wegovy are featured in this photo

US President President Trump has revealed arrangements aimed at cut the expense of widely-used weight-loss drugs, as pharmaceutical costs take center stage in his administration's messaging about accessibility.

Important Arrangements with Drug Firms

Making remarks alongside pharmaceutical executives at the executive mansion, Trump announced deals with Eli Lilly and Novo Nordisk. Consumers are set to pay from $245 to $350 monthly for weight-loss drugs like Wegovy and Eli Lilly's medication.

Numerous GLP-1 drugs, prescribed for diabetes and obesity, are priced at over $1,000 monthly without insurance or savings.

Enhanced Availability to Government Healthcare Plans

The deals will increase the company's and the manufacturer's availability to the federal health program and the state-federal health plan, the public health plans for elderly and low-income Americans.

Eli Lilly furthermore stated in a announcement it would avoid tariffs for 36 months as part of the deal with the presidential administration.

Pricing Details

Roughly 10% of Medicare recipients will be eligible for increased availability to GLP-1 treatments, and will be charged just $50, as stated by top federal officials.

Those covered by Medicaid will see a phased implementation based on when states opt in to join.

TrumpRx Website Launch

The weight-loss drugs will be offered at reduced rates on the direct-to-consumer federal platform, a government-run portal scheduled to launch by the start of the year.

Via the federal portal, Wegovy and Zepbound will be priced initially at $350 monthly usually, and drop to $250 within a couple of years. The Medicare prices of Ozempic, the weight-loss medication, Eli Lilly's treatment, and the obesity drug will be $245.

Additional Medication Options

In addition to Novo Nordisk's weight-loss injection, the pharmaceutical firm's weight-loss pill, orforglipron, will be sold for $149 for the starting amount, the manufacturer stated in a statement. The manufacturer's Zepbound will be priced at $299 for a starting dosage.

These rates are dependent on regulatory agency approval of the drugs.

Coverage Challenges

Glucagon-like peptide-1 medications are often not covered by health plans. Federal law bans the federal program from paying for the medications when employed in obesity treatment, while they typically are included when used to treat type 2 diabetes and circulatory issues. Only a dozen US states give insurance under the state-federal plan for obesity objectives.

Health Official's Statement

The top health official the administration official, speaking at the White House, stated the arrangements were products of several months of discussions with Eli Lilly and Novo Nordisk. He described overweight "the main cause of chronic disease" in the United States.

"This will be a lifesaver to individuals," Kennedy said.

"This is not a cure-all, this is not a silver bullet," he added, emphasizing the importance of eating habit modifications and physical exercise.

History of Drug Cost Discussions

Starting in summer, Trump has been pushing drug companies to cut drug prices. He dispatched messages to multiple drug companies in the warmer months, providing them 60 days to respond to his requests for more affordable rates.

Pfizer was the initial significant medication manufacturer to secure a deal with the administration, slashing prices for some drugs by nearly a large percentage on the federal portal. The company additionally committed to reduce prescription drug costs for Medicaid.

The British-Swedish firm and EMD Serono have also reached arrangements with the federal leadership in the past few weeks.

About the author

Dan Wilkerson

A fashion enthusiast and lifestyle blogger with a passion for sustainable trends and empowering women through style.

SpinStreet24

Type to search articles.